1686 related articles for article (PubMed ID: 12451476)
1. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
[TBL] [Abstract][Full Text] [Related]
3. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
[TBL] [Abstract][Full Text] [Related]
5. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
6. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Hill AB; Beck WT; Trent JM
Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
[TBL] [Abstract][Full Text] [Related]
8. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
9. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
[TBL] [Abstract][Full Text] [Related]
12. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
[TBL] [Abstract][Full Text] [Related]
13. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
15. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
16. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance.
Fu L; Liang Y; Deng L; Ding Y; Chen L; Ye Y; Yang X; Pan Q
Cancer Chemother Pharmacol; 2004 Apr; 53(4):349-56. PubMed ID: 14666379
[TBL] [Abstract][Full Text] [Related]
17. Experimental chemotherapy against xenografts derived from multidrug resistant KBv200 cells and parental drug-sensitive KB cells in nude mice by annonaceous acetogenin 89-2.
Fu LW; He LR; Liang YJ; Chen LM; Xiong HY; Yang XP; Pan QC
Yao Xue Xue Bao; 2003 Aug; 38(8):565-70. PubMed ID: 14628443
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
20. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
